Latest Biotech News

A large Chinese study published in BMJ found that HPV testing on menstrual blood collected via a sanitary-pad strip matched clinician-collected cervical samples for detection of high-risk HPV...

U.S. regulators revisited pivotal-trial adjudication issues and asked Amgen to withdraw Tavneos (avacopan), citing concerns tied to re-adjudicated endpoint data. Amgen publicly refused the...

More than two years after approval, Vertex’s CRISPR-based sickle-cell treatment Casgevy has treated only about 60 patients worldwide, with specialty centers reporting a key bottleneck:...

BC Platforms struck a deal to integrate OmicsBank’s datasets—covering over 12 million patients in India and 500,000 in the UAE—into its BC Unify platform, expanding access to genomic, imaging and...

Eikon Therapeutics priced an upsized Nasdaq offering that raised $381 million, marking the largest biotech IPO since 2024. The company said proceeds will prioritize clinical development of EIK1001...

Flagship Pioneering‑backed Generate:Biomedicines filed for an IPO, highlighting an AI-enabled discovery engine and several clinical programs including GB‑0895 (anti‑TSLP) now in phase 3. The S‑1...

Novo Nordisk told investors it expects 2026 sales and operating profit to decline—forecasting a 5–13% drop—after agreeing to U.S. price concessions for Wegovy. Executives said the company still...

Pfizer reported Phase 2 results for PF‑3944, the monthly GLP‑1 acquired via its $10B Metsera buyout, showing mean placebo‑adjusted weight loss up to ~12.3% at 28 weeks in some cohorts. The company...

The federal appropriations bill includes a provision that makes FDA‑approved multi‑cancer early detection (MCED) tests eligible for Medicare coverage, bypassing the longer USPSTF endorsement...

Regulatory scrutiny of Tavneos (avacopan) intensified after the FDA requested Amgen withdraw the drug amid questions over trial re‑adjudication and liver‑safety signals. Amgen publicly declined to...

BARDA launched the first stage of a $100 million prize competition to incentivize development of broad‑spectrum, small‑molecule antivirals targeting Togaviridae and Flaviviridae families. The...

PharosAI, a U.K. research consortium, will use 10x Genomics’ Xenium spatial platform to build multiomic, spatially resolved cancer datasets from decades of archived NHS tumor samples. Supported by...

BC Platforms signed an agreement to integrate OmicsBank datasets into its BC Unify platform, gaining access to electronic medical records, pathology slides, images, sequencing data and...

A pilot clinical trial published in Nature Biotechnology demonstrated an electrochemical, aptamer‑based wearable patch that measures drug concentrations continuously from interstitial fluid. The...

Generate:Biomedicines filed to go public, positioning an AI-driven antibody developer for Nasdaq capital markets as it advances multiple clinical-stage programs. The Flagship Pioneering–backed...

Eikon Therapeutics priced an upsized Nasdaq IPO that raised $381 million, the largest biotech public offering since 2024, to fund clinical development of multiple oncology assets. The...

Veradermics priced an upsized $256.3 million IPO to finance three pivotal trials of VDPHL-01, an oral formulation of minoxidil for pattern hair loss. The company said the proceeds will support...

Pfizer reported positive Phase 2 data from the Metsera-acquired monthly GLP-1, showing up to 12.3% placebo-adjusted weight loss at 28 weeks and tolerability comparable to peers. The company said...

Novo Nordisk warned that 2026 sales will decline materially, citing pricing dynamics and competition in the obesity market, and its stock fell sharply following the guidance. Management pointed to...

BARDA announced the first stage of a $100 million prize competition to accelerate development of broad‑spectrum small-molecule antivirals targeting Togaviridae and Flaviviridae families. HHS...